ArticleNPJ digital medicine2026
PREDICT-GBM: A multicenter platform advancing personalized glioblastoma radiotherapy planning.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Glioblastoma recurrence is largely driven by diffuse infiltration beyond radiologically visible margins, yet current radiotherapy guidelines rely on uniform margin expansions that ignore patient-specific biology and anatomy. While computational models promise to map this invisible growth and guide personalized planning, their clinical translation is hindered by a lack of standardized benchmarking and reproducible validation. To bridge this gap, we present PREDICT-GBM, an open-source platform integrating a curated, longitudinal, multi-center dataset of 243 patients with a standardized evaluation pipeline. We benchmark a novel U-Net-based recurrence prediction model against state-of-the-art biophysical and data-driven methods. Under iso-volumetric constraints, both biophysical and deep-learning approaches achieved modest but statistically significant gains in geometric coverage of future recurrence over guideline-based plans. On the combined cohort, our U-Net achieved the highest mean coverage of enhancing recurrence (79.37 ± 2.08%), surpassing guideline-based plans (paired Wilcoxon signed-rank test, Benjamini-Hochberg adjusted p = 2.9 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.